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COPD patients yields significant costs savings and has a beneficial effect on 
evaluated quality of life.
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Objectives: To estimate health care costs for asthma patients with and without 
a COPD diagnosis. MethOds: Asthma patients with and without diagnosed COPD 
were selected from the HealthCore Integrated Research Database covering admin-
istrative claims from approximately 27.6 million people in the USA. The index 
event was a patient’s first exacerbation defined as oral corticosteroid prescription 
fills or emergency department visits or inpatient visits with a primary diagnosis 
of asthma. Eligibility criteria were ≥ 1 asthma diagnosis, ≥ 1 exacerbation and 12 
months of continuous health plan enrolment on each side of the index date. Total 
all-cause and asthma-related direct health care costs for 12 months before and 
after the index date were calculated for all patients and those with and without a 
COPD diagnosis. Results: A total of 94,883 patients met all eligibility criteria, of 
these 15,127 (15.9%) had both asthma and COPD diagnoses. The mean patient age 
was 41.6 years and 62.4% were female. Co-morbid conditions were more common 
among asthma patients with a COPD diagnosis. Asthma-related direct costs repre-
sented 25-30% of all-cause direct health care costs for all patients. Among asthma 
patients, COPD and its associated co-morbidities roughly doubled all-cause and 
asthma related direct health care costs: mean annual pre-index all-cause health 
care costs were $20,012 (COPD diagnosis) versus $8,938 (no COPD diagnosis); mean 
annual pre-index asthma related costs were $5,623 (COPD diagnosis) versus $2,600 
(no COPD diagnosis). Mean annual post-index costs were almost unchanged: all-
cause costs of $21,692 (COPD diagnosis) versus $10,787 (no COPD diagnosis) and 
asthma-related costs of $5,242 (COPD diagnosis) versus $3,016 (no COPD diag-
nosis). cOnclusiOns: The economic burden of asthma among patients with a 
COPD diagnosis in a US claims database is twice as high as those without a COPD 
diagnosis. Further research could adjust for the effects of age on the prevalence 
of co-morbidities among the different groups.
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Objectives: Smoking has a tremendous impact on public health and has been a 
cause of major concern in Greece for more than twenty years. In times of economic 
recession when household income drops and health spending is decreasing, the 
demand for health services is transferred to the public sector. In light of the above, 
the aim of this study was to measure the number of smoking-related hospitaliza-
tions and the additional hospital costs for the treatment of smoking-attributable 
diseases. MethOds: A prevalence-based disease specific approach was used for the 
calculations. Greek-specific smoking-attributable fractions (SAFs) were calculated 
for all smoking-related diseases, coded according to the International Classification 
of Diseases ICD-10. Smoking attributable morbidity was obtained by applying the 
SAFs to all public hospital admissions for 2011. Total hospital costs associated with 
smoking were calculated by applying the smoking-attributable admissions to each 
DRG rate. Results: For Greece, lung cancer (C33-C34), bronchitis and emphysema 
(J40-J42, J43) presented the highest disease-specific SAF with a value of 88.4% and 
88.1% respectively. In 2011, smoking was responsible for 199,028 hospital admis-
sions (8.9 % of total). Smoking-attributable hospital costs, based on the current 
pricing DRG system, has reached 400,011,801€ representing 7.7% of public hospital 
budgets. Ischemic heart disease (I20-I25) was found to be the main cost driver (90.3 
million € ), followed by other circulatory diseases (I00-I09, I26-I51) (55.8 million€ ) and 
pneumonia, influenza (J10-J18) (52.6 million € ). cOnclusiOns: Despite evidence 
of a decreasing trend, smoking is still a considerable public health issue in Greece 
and has a great impact on public health care system. Vigorous efforts have been 
implemented to promote a smoke-free environment and to enforce existing anti-
smoking legislation however the Greek society still experiences a high proportion 
of smoking-attributable admissions and hospital treatment costs. The findings of 
this study further corroborate a call for stronger support of cost-effective tobacco 
control policies.
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Objectives: Surveys have found high rates of pain medication use among COPD 
patients. However, few data exist on how chronic pain affects health care utilization. 
We examined how chronic pain affects direct medical costs in COPD and a matched 
cohort of patients with other chronic diseases. MethOds: We conducted a retro-
spective analysis using claims data from one managed care system. COPD patients 
were matched by age, sex, insurance type, and encounter type to persons with 
other chronic conditions but without COPD [Alzheimer’s, atrial fibrillation, cancer, 
kidney disease, acute myocardial infarction, diabetes, heart failure, ischemic heart 
disease, rheumatoid/osteoarthritis (RA/OA), and stroke]. Chronic pain was indicated 
by pain-associated diagnoses, procedures for pain interventions, or prescription 
fills for pain medications. Results: The study cohort (7,952 COPD patients, 15,904 
non-COPD) was 58% female; mean age, 69. A higher percentage of COPD patients 
were chronic users of any pain medication (41.2% vs 31.5%, P< 0.0001). The only 
patients’ treatment adherence and persistence. MethOds: A systematic review 
of the literature was performed in MedLine/PubMed, Cochrane Library, ISI WOK, 
MEDES, IBECS, CSIC, Google Scholar (2002-2012) to identify articles referred to 
direct COPD cost and treatment persistence and adherence. Based on the direct 
cost data extracted, the annual cost difference between an adherent and non-
adherent and a persistent and non-persistent patient in Spain was estimated. 
Costs were updated to € , 2012. Results: A total of 48 articles were included (9 
Spanish; 39 international). The mean annual direct cost of a COPD patient in Spain 
varies between € 301 and € 4.226, depending on the publication. Patients’ adherence 
and persistence on COPD treatment and their annual costs was analyzed in 3 arti-
cles (no Spanish publications identified). Multiple inhaled treatments and devices 
of complex use contribute to poor adherence and persistence and to higher medi-
cal resources use and more exacerbations. Treatment adherence and persistence 
implies a 9% and 3% decrease in mean annual direct cost of a COPD patient, respec-
tively, while non-adherence and non-persistence means an increase of 5% and 
13%. The difference between the mean annual direct cost associated to adherent 
and to non-adherent patient varies from € 43 to € 601 (depending on the selected 
publication) and rises up to € 89 to € 1.674 in severe COPD patients. A difference 
between annual direct cost in persistent and non-persistent patient was estimated 
in € 47 to € 666 that reached € 99 to € 1.855 in severe COPD patients. cOnclusiOns: 
Treatment adherence and persistence information is scarce. Therapeutic strategies 
improving patient adherence and persistence may optimize outcomes contribute 
to COPD costs contain.
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Objectives: The Casemix databases contain clinical costing information from hos-
pitals in Malaysia, Indonesia and the Philippines. The objective of this study was to 
determine burden of pneumonia in these three countries. MethOds: Pneumonia 
cases occurring in a single year were identified using ICD10 codes, J10-J18. Patients 
were further categorized into community-acquired pneumonia (CAP) or hospital-
acquired pneumonia (HAP); CAP if they had 1) a primary diagnosis of pneumonia, 
or 2) secondary diagnosis of pneumonia with primary diagnosis of a respiratory 
condition; HAP cases had pneumonia in any of the secondary diagnosis fields with 
non-respiratory primary diagnoses. Descriptive analysis was performed to ascertain 
patient age groups, mean age, mean length of stay (LOS) and case fatality rates 
(CFR). Results: A total of 15,851 pneumonia cases in year 2010 for Indonesia and 
Philippines and 2011, for Malaysia were included in the analysis. The mean age 
of patients was 47.5 years in Malaysia, 36.6 years in Indonesia and 23.5 years in 
Philippines. There was a preponderance of CAP cases among the very young and 
the very old while HAP cases were more likely to occur in older persons. The overall 
CFR of all pneumonia hospitalizations was 11.5% for Malaysia, 5.2% for Indonesia 
and 3.6% for Philippines. The cost of hospitalization was USD 1,177.50, USD 1,103.80 
and USD 254.30 in Malaysia, Indonesia and Philippines respectively. The mean LOS 
in days was 9.2, 8.0 and 6.6 in the three countries, respectively. cOnclusiOns: 
Our study is the first to utilize these databases to study and compare the burden of 
pneumonia across three countries in Asia. The CFR and LOS varied in each of the 
countries likely due to a variety of reasons including differences in socio-economic 
conditions, patterns of infection as well as health system differences. In conclu-
sion, pneumonia is significant burden in the South East Asian countries studied.
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Objectives: To evaluate cost and cost-effectiveness of tiotropium monotherapy 
administered for 24 months (18 mcg die) in patients suffering from mild-to-
moderate and severe chronic obstructive pulmonary disease (COPD). MethOds: 
A recent published study showed that tiotropium monotherapy enables a sig-
nificant minimization of morbidity in two groups of patients corresponding to 
predicted FEV1 baseline values ≤ 50% (A) and > 50% (B). Clinical outcomes (days 
in hospital, visits in general ward, cycles of systemic steroids, cycles of antibiotics 
and maintenance therapy drugs) were evaluated from the Italian NHS perspective. 
In order to perform cost-effectiveness analysis, FEV1 value, available for each 
patient, was converted in SGRQ score using a published multivariate linear model; 
then utilities were obtained through the Ståhl equation. Results: Results from 
comparison between 24 months of standard therapy and subsequent 24 months 
of tiotropium monotherapy show that hospitalization cost, which represents the 
driving treatment cost, drops from 74.1% to 67.3% (A) and from 64.5% to 31.6% 
(B) of the total cost; differently maintenance therapy cost increases but it is 
more than offset by the savings accruing from the shortening of hospitalization. 
Furthermore, cost-effectiveness results reveal a mean saving of 216 € (A) and 
900 € (B) other than a mean gain of 0.07 QALY(A) and 0.03 QALY(B). Dominance 
of tiotropium calculated only with patients completing treatment course reveal 
that in almost 30% (A) and 37% (B) of subjects tiotropium strategy is dominant 
while only in 2% (A) and 7% (B) of cases are associated to costs increment and 
worsening on quality of life. cOnclusiOns: These results suggest that adop-
tion of tiotropium as unique treatment in selected mild-to-moderate and severe 
